瑞银上调爵士制药评级：核心业务韧性强劲，新药Ziihera成增长引擎

环球市场播报05-19

瑞银集团周一上调了爵士制药的股票评级，原因在于其核心业务的韧性和一款癌症治疗药物的商业化潜力令该行转为看涨。　　瑞银将爵士制药的评级从“中性”上调至“买入”，并将目标价大幅上调至307美元。这一目标价较周一收盘价意味着超过33%的上涨空间。分析师阿什瓦尼·维尔马在周二的一份报告中指出，该公司用于治疗胆囊癌的药物Ziihera即将在8月25日的法定截止日期前实现快速使用和获批。但他同时写道，公司的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2636851188?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-19 21:19","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2636851188","market":"sh","top_or_hot":-1,"title":"瑞银上调爵士制药评级：核心业务韧性强劲，新药Ziihera成增长引擎","media":"环球市场播报","content":"<div>\n<p>瑞银集团周一上调了爵士制药的股票评级，原因在于其核心业务的韧性和一款癌症治疗药物的商业化潜力令该行转为看涨。\n　　瑞银将爵士制药的评级从“中性”上调至“买入”，并将目标价大幅上调至307美元。这一目标价较周一收盘价意味着超过33%的上涨空间。分析师阿什瓦尼·维尔马在周二的一份报告中指出，该公司用于治疗胆囊癌的药物Ziihera即将在8月25日的法定截止日期前实现快速使用和获批。但他同时写道，公司的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymysz9816824.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞银上调爵士制药评级：核心业务韧性强劲，新药Ziihera成增长引擎</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞银上调爵士制药评级：核心业务韧性强劲，新药Ziihera成增长引擎\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-19 21:19 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymysz9816824.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>瑞银集团周一上调了爵士制药的股票评级，原因在于其核心业务的韧性和一款癌症治疗药物的商业化潜力令该行转为看涨。\n　　瑞银将爵士制药的评级从“中性”上调至“买入”，并将目标价大幅上调至307美元。这一目标价较周一收盘价意味着超过33%的上涨空间。分析师阿什瓦尼·维尔马在周二的一份报告中指出，该公司用于治疗胆囊癌的药物Ziihera即将在8月25日的法定截止日期前实现快速使用和获批。但他同时写道，公司的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymysz9816824.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymysz9816824.shtml","article_id":"2636851188","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636851188","pubTimestamp":1779196740,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"瑞银集团周一上调了爵士制药的股票评级，原因在于其核心业务的韧性和一款癌症治疗药物的商业化潜力令该行转为看涨。　　瑞银将爵士制药的评级从“中性”上调至“买入”，并将目标价大幅上调至307美元。分析师阿什瓦尼·维尔马在周二的一份报告中指出，该公司用于治疗胆囊癌的药物Ziihera即将在8月25日的法定截止日期前实现快速使用和获批。　　2026年以来，爵士制药的股价已累计上涨35%，过去一年更是翻了一番。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"UBS upgrades Jazz Pharmaceuticals: core business resilience is strong, new drug Ziihera becomes a growth engine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1.5},"content_text":"瑞银集团周一上调了爵士制药的股票评级，原因在于其核心业务的韧性和一款癌症治疗药物的商业化潜力令该行转为看涨。\n　　瑞银将爵士制药的评级从“中性”上调至“买入”，并将目标价大幅上调至307美元。这一目标价较周一收盘价意味着超过33%的上涨空间。分析师阿什瓦尼·维尔马在周二的一份报告中指出，该公司用于治疗胆囊癌的药物Ziihera即将在8月25日的法定截止日期前实现快速使用和获批。但他同时写道，公司的其他业务也同样表现良好。\n　　维尔马表示：“我们认为，面对价格压力以及2026年下半年Orexin竞品的进入，睡眠障碍药物业务线的稳定性似乎是可控的，而Ziihera所代表的新的增长机遇更是使其相形见绌。此外，在未来一两年内，用于治疗一种脑癌的药物Modeyso有望产生可观的销售额。”\n　　2026年以来，爵士制药的股价已累计上涨35%，过去一年更是翻了一番。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636851188","isCrawlerRequest":true}